Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 245-252    DOI: 10.31083/j.ceog.2021.02.2265
Systematic Review Previous articles | Next articles
Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis
Yi Zhou1, Ran Wang2, Shi-Xian Chen2, Li-Sheng Wu2, 3, *(), Jun-Qing Zhu2, *()
1Department of Obstetrics, Guangdong Women and Children Hospital, 510510 Guangzhou, Guangdong, China
2Department of Rheumatic & TCM Medical Center, Nanfang Hospital, Southern Medical University, 510510 Guangzhou, Guangdong, China
3Department of Internal Medicine of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Southern Medical University, 510510 Guangzhou, Guangdong, China
Download:  PDF(1693KB)  ( 116 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Hypertensive disorders of pregnancy (HDP) encompass a group of diseases. Single nucleotide polymorphisms (SNPs) are common in the matrix metalloproteinase 9 (MMP9) genes. The objective of this study was to analyse whether genetic polymorphisms in MMP9-1562 C/T alter the risk of HDP. Studies published up to October 2019 across PubMed, ScienceDirect, SpringerLink, and China National Knowledge Infrastructure database were searched. Case-control or cohort studies involving subtypes of HDP and distribution of genotypes and/or alleles within MMP9-1562 C/T in both patients and controls were selected. Number of genotypes and/or alleles for MMP9-1562 C/T polymorphisms were obtained and analyzed using Stata software. Eight published reports including 1300 HDP patients and 1612 controls were included in the meta-analysis. Results showed that a variant genotype and allele of MMP9-1562 C/T increased the risk of HDP, with pooled OR 1.50 (95% CI 1.16–1.95, P = 0.002) and 1.36 (95% CI 1.15–1.61, P < 0.001). Subgroup analyses showed that the variant genotype and allele of MMP9-1562 C/T also had increased risk of preeclampsia (OR = 1.48, 1.32; 95% CI 1.18–1.86, 1.08–1.62; P = 0.001, 0.007) and gestational hypertension (OR = 2.23, 1.88; 95% CI 1.52–3.28, 1.33–2.65; P < 0.001, < 0.001) in the fixed-effects models. This suggests that variant genotype (TT + TC) and allele (T) of MMP9-1562 C/T are associated with susceptibility of HDP, especially preeclampsia and gestational hypertension.
Key words:  Hypertensive disorders of pregnancy      Gestational hypertension      Preeclampsia      Matrix metalloproteinase 9      Single nucleotide polymorphism     
Submitted:  20 August 2020      Revised:  03 November 2020      Accepted:  16 November 2020      Published:  15 April 2021     
Fund: 
81803932/Natural Science Foundation of China
2018030310025/Natural Science Foundation of Guangdong Province
2017A030313868/Natural Science Foundation of Guangdong Province
2017Z020 and 2016C024/President Foundation of Nanfang Hospital, Southern Medical University
*Corresponding Author(s):  jqzhujq@yeah.net (Jun-Qing Zhu); wlslu@smu.edu.cn (Li-Sheng Wu)   

Cite this article: 

Yi Zhou, Ran Wang, Shi-Xian Chen, Li-Sheng Wu, Jun-Qing Zhu. Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 245-252.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2265     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/245

[1] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[2] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[3] Shingo Tanaka, Maki Goto, Saya Watanabe, Sachino Kira, Sotaro Hayashi, Shigeki Fujimoto, Miho Oda, Lifa Lee, Yoko To, Satoshi Nishiyama, Fuyuki Eguchi, Hiroshi Tsujioka. Posterior reversible encephalopathy syndrome with reversible cerebral vasoconstriction syndrome in a normal primigravida woman at the 35-week gestational stage: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 982-986.
[4] Lejla Kamerić, Anis Cerovac, Mirzeta Rizvanović, Alen Kamerić, Mahira Jahić, Dubravko Habek. Frequency of cesarean section in pregnant women with risk factors for preeclampsia: prospective cohort study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 561-566.
[5] Elisa Casella, Carla Ettore, Ferdinando Antonio Gulino, Elisa Pappalardo, Filippo Rapisarda, Stella Capriglione, Giuseppe Ettore. Two successful pregnancies after a simultaneous kidney and pancreas transplantation for type 1 diabetes mellitus-complicated nephropathy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 697-699.
[6] Jing Wang, Min Zhou, Li Zhang, Long-Xin Zhang. Effective doses 50% and 95% of subarachnoid injection of sufentanil with ropivacaine in lumbar anesthesia for cesarean section in severe preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 105-109.
[7] R. Mihăilă. Coagulation challenges in pregnancy: from thrombophilia involvement and management to the utility of thrombin generation monitoring[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 814-820.
[8] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
[9] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[10] A. E. Kholeif, M. Y. Khamis, S. Eltabakh, R. S. Swilam, A. Elhabashy, R. EISherif. Prediction of severity of preeclampsia in Egyptian patients: role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and C-reactive protein[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 183-188.
[11] J. Yoon Park, S.W. Lee, K.J. Oh, J.-S. Hong. High mean blood pressure during the first trimester is predictive of future preeclampsia development in healthy pregnant women: a cohort study in Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 770-775.
[12] M. Trisovic, O. Mladenovic, J. Bila, K. Lalić, D. Kisic Tepavcevic. The predictive value of metabolic syndrome in the evaluation of pregnancy course and outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 776-778.
[13] Y. E. Purut, E. E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A. Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.
[14] E. Ertekin, Ö. Tunçyürek, S. Kafkas, Y. Özsunar. Does the placental strain ratio correlate with the umbilical artery Doppler values?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 227-230.
[15] A. Simsek, S. Uludag, A. Tuten, A. S. Acikgoz, S. Uludag. Maternal and perinatal outcomes in early onset and late onset preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 837-841.
No Suggested Reading articles found!